Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs WOCKHARDT - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA WOCKHARDT CIPLA/
WOCKHARDT
 
P/E (TTM) x 35.3 -88.9 - View Chart
P/BV x 4.1 2.0 208.1% View Chart
Dividend Yield % 0.5 0.0 25,476.1%  

Financials

 CIPLA   WOCKHARDT
EQUITY SHARE DATA
    CIPLA
Mar-20
WOCKHARDT
Mar-18
CIPLA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs5861,012 57.9%   
Low Rs357532 67.1%   
Sales per share (Unadj.) Rs207.0355.9 58.2%  
Earnings per share (Unadj.) Rs18.6-60.3 -30.9%  
Cash flow per share (Unadj.) Rs33.2-46.8 -70.9%  
Dividends per share (Unadj.) Rs4.000.01 40,000.0%  
Dividend yield (eoy) %0.80 65,520.5%  
Book value per share (Unadj.) Rs195.5257.8 75.8%  
Shares outstanding (eoy) m806.35110.63 728.9%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.32.2 104.9%   
Avg P/E ratio x25.3-12.8 -197.9%  
P/CF ratio (eoy) x14.2-16.5 -86.1%  
Price / Book Value ratio x2.43.0 80.5%  
Dividend payout %21.50 -129,654.2%   
Avg Mkt Cap Rs m379,91285,379 445.0%   
No. of employees `00025.86.3 413.3%   
Total wages/salary Rs m30,2709,371 323.0%   
Avg. sales/employee Rs Th6,459.66,295.0 102.6%   
Avg. wages/employee Rs Th1,171.21,498.3 78.2%   
Avg. net profit/employee Rs Th580.2-1,066.3 -54.4%   
INCOME DATA
Net Sales Rs m166,94939,369 424.1%  
Other income Rs m3,4421,202 286.3%   
Total revenues Rs m170,39140,571 420.0%   
Gross profit Rs m32,06018 175,190.7%  
Depreciation Rs m11,7471,495 785.6%   
Interest Rs m1,9742,555 77.2%   
Profit before tax Rs m21,782-2,830 -769.8%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m6,312257 2,456.0%   
Profit after tax Rs m14,995-6,669 -224.9%  
Gross profit margin %19.20 41,312.6%  
Effective tax rate %29.0-9.1 -319.1%   
Net profit margin %9.0-16.9 -53.0%  
BALANCE SHEET DATA
Current assets Rs m117,03833,796 346.3%   
Current liabilities Rs m43,93126,917 163.2%   
Net working cap to sales %43.817.5 250.6%  
Current ratio x2.71.3 212.2%  
Inventory Days Days9679 120.6%  
Debtors Days Days8589 95.3%  
Net fixed assets Rs m107,42439,664 270.8%   
Share capital Rs m1,613553 291.5%   
"Free" reserves Rs m156,01827,968 557.8%   
Net worth Rs m157,63028,522 552.7%   
Long term debt Rs m23,69321,731 109.0%   
Total assets Rs m236,62681,620 289.9%  
Interest coverage x12.0-0.1 -11,194.9%   
Debt to equity ratio x0.20.8 19.7%  
Sales to assets ratio x0.70.5 146.3%   
Return on assets %7.2-5.0 -142.3%  
Return on equity %9.5-23.4 -40.7%  
Return on capital %12.8-7.7 -167.3%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,0369,807 571.4%   
Fx outflow Rs m6,7641,789 378.2%   
Net fx Rs m49,2728,019 614.5%   
CASH FLOW
From Operations Rs m30,685684 4,483.4%  
From Investments Rs m1,0406,302 16.5%  
From Financial Activity Rs m-29,488-7,695 383.2%  
Net Cashflow Rs m2,340-664 -352.4%  

Share Holding

Indian Promoters % 16.0 74.5 21.5%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 2.3 530.4%  
FIIs % 23.7 7.7 307.8%  
ADR/GDR % 1.1 0.1 1,100.0%  
Free float % 26.2 15.4 170.1%  
Shareholders   161,166 67,757 237.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   AUROBINDO PHARMA  ORCHID PHARMA  NOVARTIS  FULFORD INDIA  SHASUN PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 470 Points Lower; Tata Motors & Tata Steel Fall 6%(Closing)

Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.

Related Views on News

ASTRAZENECA PHARMA Share Price Down by 5%; BSE HEALTHCARE Index Down 2.5% (Market Updates)

Jan 18, 2021 | Updated on Jan 18, 2021

ASTRAZENECA PHARMA share price is trading down by 5% and its current market price is Rs 4,200. The BSE HEALTHCARE is down by 2.5%. The top gainers in the BSE HEALTHCARE Index are GSK PHARMA (up 1.2%) and IPCA LABS (up 1.0%). The top losers are ASTRAZENECA PHARMA (down 5.3%) and WOCKHARDT (down 5.2%).

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 18, 2021 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS